Wal-Mart, the world's largest retailer, whose $4 per month discounted generic drug program (Marketletters passim) triggered a price war in the US pharmacy market, has reported a massive increase in the number of Internet orders it has processed since the scheme began in late September.
Walmart.com (Wal-Mart's on-line outlet) chief executive Carter Cast told the Bloomberg news service that the site had recorded "triple-digit growth" in generic drug sales since the $4 program started, the biggest surge in any of the store's sales areas since the web site was launched in 1996.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze